BroadOak Capital Partners


BroadOak Capital Partners is a boutique financial institution focused on the life sciences sector. Since 2006, they have been providing direct investment and investment banking services to companies in life sciences tools, diagnostics, and biopharma services sectors. With over 15 years of experience, BroadOak has made investments in more than 70 companies and advised on over 50 successful M&A transactions, helping life sciences businesses achieve their full potential.

BroadOak Capital Partners

BroadOak Capital Partners


What We Do

Services to help management teams optimize sale processes, mergers, acquisitions, and financing.


Investment Range


Portfolio

Rubicon Founders invested in Horizon Infusions with support from BroadOak.

#Healthcare

Advised on sale to Werfen.

#Biotechnology

Raised $12 million to expand continuous biomanufacturing product line.

#Biomanufacturing

Specializes in micronization and particle size control.

#Pharmaceutical Services

Specializes in the production of novel proteins.

#Biotechnology

Acquired Interpace’s Pharma Services Business.

#Biotechnology

Enables automated lab processes.

#Technology

Advised on sale to Oncodesign Services.

#Biotechnology

Acquired A4P Bio.

#Clinical Trials

Sold to Medix Biochemica.

#IVD Industry

Acquired by Biosynth Carbosynth.

#Clinical Diagnostics

Acquired antibodies-online with financing from BroadOak.

#Biotechnology